XML 43 R27.htm IDEA: XBRL DOCUMENT v3.20.2
Revenue Recognition and Contractual Adjustments (Tables)
 9 Months Ended
Sep. 30, 2020
Revenue from Contract with Customer [Abstract]  
Summary of Contract Assets and Liabilities
The following table summarizes the values of contract assets, capitalized commissions and contract liabilities as of September 30, 2020 and December 31, 2019 (in thousands):

September 30, 2020December 31, 2019
Current pharma contract assets (1)
$1,533 $1,000 
Long-term pharma contract assets (2)
271 153 
Total pharma contract assets$1,804 $1,153 
Current pharma capitalized commissions (1)
$160 $133 
Long-term pharma capitalized commissions (2)
809 798 
Total pharma capitalized commissions$969 $931 
Current pharma contract liabilities$3,716 $1,610 
Long-term pharma contract liabilities (3)
657 1,171 
Total pharma contract liabilities$4,373 $2,781 
(1) Current pharma contract assets and Current pharma capitalized commissions are classified as “Other current assets” on the Consolidated Balance Sheets.
(2) Long-term pharma contract assets and Long-term pharma capitalized commissions are classified as “Other assets” on the Consolidated Balance Sheets.
(3) Long-term pharma contract liabilities are classified as “Other long-term liabilities” on the Consolidated Balance Sheets.
Summary of Disaggregation of Revenue
The following table details the disaggregation of revenue for both the Clinical and Pharma Services Segments (in thousands):
Three Months Ended September 30,Nine Months Ended September 30,
2020201920202019
Clinical Services:
    Client direct billing$72,896 $53,555 $172,431 $155,999 
    Commercial Insurance19,218 20,956 56,360 63,052 
    Medicare and Medicaid16,460 17,818 46,484 47,961 
    Self-Pay159 236 324 745 
Total Clinical Services $108,733 $92,565 $275,599 $267,757 
Pharma Services:16,711 12,107 42,852 34,205 
Total Revenue$125,444 $104,672 $318,451 $301,962